We would love to hear your thoughts about our site and services, please take our survey here.
Nail on the head their Lou. Parsortix is carving out its own market leading biomarkers in areas that its competitors are either unable to address on an individual level leading to multiple tests and therefore an increase in cost, or that it’s an unmet need.
Money talks. I expect it to be a drawn out transaction, but after previous failed transactions, they would of been prepared for this.
Inivata platform for CtDNA (recovery of dead DNA cells) compliments NeoGonomics existing product mix as the AI ctDNA companies posture for market share and a competitive edge. M&A within the industry has been rife with the sector awash with cash (+$5b raised in the last two years alone). This is indicative of a very large market in the making ($140b+ annually).
Parsortix is a different kettle of fish and the business model is to act not as a competitor but as a companion or complimentary diagnostic tool. Unlike the competition, Parsortix is not just offered as a service but product, which is a compelling competitive edge when looking to offer not just DNA but RNA and protein analysis (blueprint). Refer to the proposed Illumina takeover of Grail and why the various competition bodies are trying to block the takeover. (Product v service)
A lot can be said for first mover advantage and the potential forthcoming FDA approval when it comes to commercial traction for AGL, you could argue that they are a sleeping giant, and one decision and a Nasdaq listing away from mixing it with the big boys, IF the big boys allow AGL to get that far which is the current ???
Based on the research I have done to date, it is my belief that Parsortix will become the PD-L1 assay of choice to act as a ‘companion’ or ‘complementary’ diagnostic alongside these two drug candidates from AstraZeneca.
On this board I had offered links to AZ. funded research papers and similar biomarker deals to provide an element of information that had helped me to reach this conclusion which may or may not be wrong.
‘ANGLE has established a dialogue with prospective customers and collaborators for the deployment of PD-L1 analysis capabilities in pharma services cancer drug trials.’ (Prelims last week).
What this would do for the projected $1.2b annual opportunity for the company and its market cap prior to the future Nasdaq listing would be immeasurable, providing further credibility to its IP.
We know that the existing company resources are allocated towards the Ovarian, Breast Cancer and Pharma services division, therefore further PD-L1 clinical trials as a companion would make sense to be funded via a collaboration with a major household name or similar.
Further credibility is provided from the prelim webcast and the direct reference to ‘bespoke assays’ as biomarkers to specific analytes as a companion to specific drugs that may or may not of passed previous trials due to identification of eligible patients.
Market is massive and the company referred to an expansion or resources in this area, something that would of not be mentioned had they not of had a specific agenda in/for this area.
Tom, his last post was ‘major correction’, he has his own agenda.
AstraZeneca do not fund research papers for specific companion tools (parsortix) linked to its own drugs for no reason. Don’t worry not everyone will agree with us.
I think I bought his shares last week :-)
I keep coming back to the deal that AstraZeneca did with Guardant health in 2018 for two separate biomarkers/companion diagnostics. One of these diagnostics happened to be for Tagrisso, an EGFR inhibitor.
https://www.fiercebiotech.com/medtech/guardant-to-develop-cdx-and-tmb-liquid-biopsy-tests-for-astrazeneca-s-targeted-cancer
This inhibitor formed part of an AstraZeneca funded Parsortix study which showed to offer a critical advantage over other liquid biopsy approaches in providing information in clinical trials. It added: "Findings support Angle's plan for the growth of a new 'pharma services' business area using the Parsortix system as a biomarker for cancer drug trials allowing longitudinal monitoring of patients."
https://www.morningstar.co.uk/uk/news/AN_1612804142187001900/in-brief-angle-says-athens-university-study-shows-value-of-parsortix.aspx
To then consider a comment that stuck with me from the recent prelim RNS, and the household names they are in discussions with, ‘ANGLE has established a dialogue with prospective customers and collaborators for the deployment of PD-L1 analysis capabilities in pharma services cancer drug trials.’
https://uk.advfn.com/stock-market/london/angle-AGL/share-news/Angle-PLC-Preliminary-Results/84946842
I quote ‘collaborators’, I can’t help but think that the likes of AstraZeneca have a role to play in the short term which could transform the commercial outlook of AGL.
Your optimism isn’t misplaced, you are invested in a company going places :-)
Unfortunately it’s an illiquid listing with volume in the hundreds, your lucky to have to use more than one hand for total number of trades in a day.
Can’t really be used for anything other than a stepping stone towards the future Nasdaq listing that AGL are working towards, alongside the change of accounting periods and the appointment of PWC.
It does feel as if the share has further momentum to the upside with a recently released peer reviewed paper, yet to hit the market as a non-RNS but has a certain level of weight that isn’t priced in yet Imo. AIR submission and further Pharma services contracts all expected in the month of May.
I thin
I believe this is where hycead ziplex system, part of the future parsortix upgrade (which will take the market by surprise), as part of the sample to answer system has a massive role to play both now and in the future.
As per the comments in the prelims regarding specific biomarkers (protein) and the current best practice identifying CA125 which is the non specific, low specificity and sensitivity for Ovarian. Breast cancer will also have specific identifiable biomarkers.
As you know with parsortix, it doesn’t just stop at identification and confirmation of disease, but a tool to identify suitable drugs reducing both financial wastage and improving patient outcomes.
I too am no expert, but reading between the lines with a culmination of research.
Have stifel flipped back to the buy side. WNTS drove us down and now up based on L2 today.
Thanks for link. To many are treating this, and holding this back on the basis of thinking it’s all about the FDA decision.
It’s game on now. Undervalued at these levels.
In anticipation of higher future prices. Analysts present on the webcast would find it hard to not be excited by companies prospects.
P25, the trades at 103.5p were all buys were they not? My dummy sells at the time weren’t at 103.5p, those purchases contributed towards the bounce.
Exactly P - like many other companies in the US, AGL are able to establish a significant revenue base without an FDA approval. Only that FDA would double the market opportunity and accelerate partner discussions across a broader range of cancer targets.
Only thing to do now is sit on my hands and add when I can afford to as this is one hell of a company in the making backed up with solid fundamentals.
If Stifel are presenting a market opportunity to buy at lower prices, let them crack on as it won’t last forever, and in the meantime allows for a lower/higher average.
As expected this was a fantastic presentation which only goes on to highlight the companies belief that they can one day compete with the multibillion valuation of its peers. My opinion is that this is a lot closer than the UK market is currently giving it credit for.
With a magnitude of talks taking place across the board for both new Pharma contracts and collaboration partnerships, this is only going in one direction.
RSI has cooled off. This very much had the feel of a margin call, why else would you dump stock so aggressively on the prelims when such great info is coming out and webcast adds more color.
My strategy for 2021 and AGL is now to hold 100% of my position through the FDA decision. I feel that with the Pharma services and future Clea lab assays such as the Ovarian test opening up, that I can comfortably hold this stock through this pivotal decision. In my opinion the present price/market cap would be more than justified by positive verification results from the Ovarian study, as it opens up another billion dollar plus opportunity.
To see continued success with the Pharma Sevices division, securing further contracts only adds to the now derisked proposition.
I would argue that in 12 months from now, even if the FDA decision goes against us, it would be reasonable to assume that all other things considered, the share price would be at least equal to what it is today. Unless of course you see no future in the Ovarian and PD-L1 market opportunities.
To then see the assumed and likely fda approval, well effectively I believe you can currently hold that upside for free depending on your investment time horizon.
This is not a boom or bust stock anymore, thus the re-rating and likely continued move higher over time.
Something can be said for a continued accumulation of stock without a TR1, but in general I think it’s more likely that this has the attention of a growing number of high net worth individuals.
It’s impossible to ignore the multiple multi billion dollar opportunities that are opening up.
This won’t require FDA approval, this is the verification study prior to distribution within the CLR lab. With the lab being validated by year end in conjunction with this ready for immediate distribution.
$2b market then dominated with AGL’s 95%+ sensitivity assay when nearest competition is 25/30%. Game changer.